Needham & Company LLC Reaffirms “Buy” Rating for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a report released on Monday,Benzinga reports. They currently have a $77.00 target price on the medical equipment provider’s stock. Needham & Company LLC’s price target suggests a potential upside of 39.14% from the stock’s current price.

Several other brokerages also recently weighed in on BSX. Jefferies Financial Group cut their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Wells Fargo & Company cut their price objective on shares of Boston Scientific from $94.00 to $75.00 and set an “overweight” rating on the stock in a research report on Thursday, April 23rd. BTIG Research reiterated a “buy” rating and issued a $80.00 price objective on shares of Boston Scientific in a research report on Monday. TD Cowen cut their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Finally, Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.83.

Boston Scientific Stock Performance

Shares of Boston Scientific stock traded up $2.66 during trading hours on Monday, reaching $55.34. The company’s stock had a trading volume of 7,206,940 shares, compared to its average volume of 16,500,674. The company’s 50 day simple moving average is $63.40 and its 200 day simple moving average is $81.65. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific has a one year low of $52.52 and a one year high of $109.50. The stock has a market cap of $82.24 billion, a P/E ratio of 23.15, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period last year, the firm posted $0.75 EPS. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts expect that Boston Scientific will post 3.38 EPS for the current fiscal year.

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in BSX. Brighton Jones LLC raised its position in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares in the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter worth about $26,000. Main Street Financial Solutions LLC raised its position in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after buying an additional 1,971 shares in the last quarter. Ieq Capital LLC raised its position in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after buying an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC raised its position in shares of Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after buying an additional 2,556 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific announced a $1.5 billion strategic investment in MiRus LLC, giving it about a 34% stake and an exclusive option to acquire MiRus’ structural heart/TAVR business after clinical and regulatory milestones. Investors may view this as a meaningful long-term growth catalyst in the fast-growing transcatheter aortic valve market.
• Positive Sentiment: The company also launched a $2 billion accelerated share repurchase as part of its existing buyback authorization. That kind of buyback can support earnings per share and signals management confidence in Boston Scientific’s outlook.
• Positive Sentiment: BTIG reaffirmed its Buy rating on BSX and maintained a $80 price target, reinforcing the view that analysts still see upside from current levels.
• Neutral Sentiment: There was also broader pressure on healthcare stocks in premarket trading, which may have offset some of the company-specific enthusiasm.
• Negative Sentiment: Recent insider trading data shows multiple executive sales over the past six months, which is not a major near-term driver but can temper sentiment for some investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.